Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Allergan's generics business (2016)
acquired several smaller pharmaceutical companies Actavis_(2016) |
| gptkbp:advertising |
focuses on cost-effective medications
|
| gptkbp:CEO |
Kåre Schultz
|
| gptkbp:challenges |
faced financial difficulties in recent years
|
| gptkbp:clinicalTrials |
conducts numerous clinical trials globally
|
| gptkbp:community_engagement |
supports various health initiatives
|
| gptkbp:community_outreach |
engages in community outreach programs.
|
| gptkbp:competitors |
faces competition from other generic manufacturers
|
| gptkbp:culturalHeritage |
diversified product portfolio
|
| gptkbp:dividendYield |
has a history of paying dividends
|
| gptkbp:employees |
over 40,000
|
| gptkbp:financialPerformance |
volatile stock performance
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
gptkb:Eli_Hurvitz
|
| gptkbp:global_presence |
operates in over 60 countries
|
| gptkbp:headCoach |
approximately 38,000 (2021)
|
| gptkbp:headquarters |
Petah_Tikva,_Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
TEVA
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:internationalRelations |
generates significant revenue from international sales
|
| gptkbp:investmentFocus |
invests in innovative drug development
|
| gptkbp:leadership |
experienced changes in executive leadership
|
| gptkbp:legal_principle |
faced multiple lawsuits regarding opioid crisis
|
| gptkbp:market |
approximately $10 billion (2021)
|
| gptkbp:market_segment |
one of the largest in the world
|
| gptkbp:notableEvent |
gptkb:Vascepa
Procrit Ajovy Treanda Copaxone |
| gptkbp:partnerships |
partners with healthcare providers
collaborates with various biotech firms |
| gptkbp:patentCitation |
holds thousands of patents worldwide
|
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:recalls |
has issued product recalls in the past
|
| gptkbp:regulatoryCompliance |
must_comply_with_FDA_regulations
|
| gptkbp:research_focus |
focuses on neurological and oncology therapies
|
| gptkbp:researchAndDevelopment |
invests over $1 billion annually
|
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:social_responsibility |
engages in corporate social responsibility initiatives
|
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:TEVA
has engaged in stock buyback programs |
| gptkbp:subsidiary |
gptkb:Teva_Pharmaceuticals_USA
gptkb:Teva_Canada_Limited gptkb:Teva_UK_Limited gptkb:Teva_Pharmaceuticals_Europe_B.V. |
| gptkbp:sustainability_initiatives |
committed to sustainability practices
|
| gptkbp:training |
provides extensive employee training programs
|